On Wednesday, May 6, Cellectis held their Q1 2020 earnings call (press release). The company stated that they have experienced limited disruption from COVID-19 and continue to progress with their CAR-T clinical trials and manufacturing expansion activities. Below, FENIX provides highlights and insights from the call, including how Cellectis’s ability to avoid delays to key strategic programs could help maintain its position as a leading cell therapy company developing allogeneic CAR-Ts for AML, ALL, and MM.